N/A N=12 Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis
Atopic Keratoconjunctivitis
Primary: Ocular Symptoms and Signs Total Composite Score — 29.1; 4.7 units on a scale — p=0.002
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=176 Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis
Atopic Conjunctivitis
Primary: Percentage of Treatment Responders — 21.3; 17.2 Percentage of Patients
Phase 3 N=745 Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca
Primary: Tear Production — 16.6; 9.2 Percentage of eyes
Phase 3 N=455 Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca · Dry Eye Disease
Primary: Conjunctival Staining — -1.9; -1.8; -1.2 score on a scale
Phase 4 N=13 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients
Allergic Conjunctivitis
Primary: Patient-Assessed Ocular Itching — 2.2; 2.2; 0.5; 0.5 units on a scale
Phase 2 N=80 Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca
Primary: Change From Baseline to Week 12 in Schirmer Test (ST) Score in Millimeters — 1.25; 3.81 Millimeters — p=0.027
Phase 4 N=23 Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Change From Baseline in Ocular Itching at 14 Days — 2.17; 1.82 units on a scale
Phase 3 N=345 Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Mean Ocular Itching at Onset of Action — 0.38; 0.47; 0.59; 1.91 units on a scale
Phase 3 N=73 OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
Chronic Allergic Conjunctivitis
Primary: Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6 — 1.68; 2.66 units on a scale
Phase 3 N=258 An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca
Primary: Adverse Events — 68; 81 Count of participants
Phase 2 N=68 OTX-14-001: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
Chronic Allergic Conjunctivitis
Primary: Ocular Itching — 1.80; 2.58; 1.72; 2.70 units on a scale (0 -4)
Phase 3 N=86 OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
Chronic Allergic Conjunctivitis
Primary: Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6 — 2.04; 2.31 units on a scale
Phase 2 N=154 A Study of ADX-102 in Subjects With Allergic Conjunctivitis
Conjunctivitis, Allergic
Primary: Ocular Itching Evaluated by the Subject at 10(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15. — 2.020; 2.398; 2.515 units on a scale
Phase 3 N=101 Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model
Allergic Conjunctivitis
Primary: Ocular Itching at Duration of Action (16 Hours Post-dose) — 1.91; 2.00; 1.65; 2.48 units on a scale
Phase 4 N=36 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
Allergic Conjunctivitis
Primary: Ocular Itching at Baseline (Day 0) — 2.53; 3.08; 2.61; 2.5 units on a scale
Phase 2 N=102 Exploratory Study of OPC-12759 Ophthalmic Suspension
Keratoconjunctival Epithelial Disorder
Primary: Change in the Keratoconjunctival Staining Score From Baseline — -3.4; -3.1 scores on a scale — p=0.576
Phase 2 N=204 To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca
Primary: Change of Corneal Fluorescein Staining of the Inferior Cornea Region. — -1.00; -0.78; -0.78 units on a scale (Likert)
Phase 3 N=202 Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model
Allergic Conjunctivitis
Primary: Mean Ocular Itching at Onset of Action — 0.4; 1.9; 0.4; 0.6 Units on a scale
Phase 4 N=18 Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis
Hypersensitivity
Primary: Symptoms — 15.3; 11.3; 13.3; 9.8 Units on a scale
Phase 3 N=96 A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6 (7 Days Post-insertion) — 1.80; 2.69 units on a scale
Phase 3 N=130 Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Ocular Itching — 0.4; 1.9; 0.4; 0.5 Units on a scale
Phase 3 N=141 Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.
Allergic Conjunctivitis
Primary: Ocular Itching — 0.43; 0.40; 1.60; 1.81 score on a scale
Phase 2 N=83 Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model
Allergic Conjunctivitis
Primary: Ocular Itching at Onset of Action (15 Minutes Post-dose) — 1.33; 0.99; 2.11; 2.90 units on a scale
Phase 4 N=11 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
Allergic Conjunctivitis
Primary: Ocular Itching Change From Baseline to Day 11 — -1.1; -0.45 units on a scale
Phase 3 N=357 Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis
Conjunctivitis · Keratitis · Blepharitis
Primary: Signs and Symptoms Composite Score - Change From Baseline to Day 15 - PP Population — -11.63; -12.41 Scores on a scale
Phase 2 N=102 Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)
Keratoconjunctivitis Sicca
Primary: Change From Baseline in Corneal Total Fluorescein Staining Score at for the Study Eye at Week 4 — -1.3; -1.7; -1.3 units on a scale — p=0.6199
Phase 3 N=144 Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.
Allergic Conjunctivitis
Primary: Ocular Itching — 0.50; 0.49; 1.87; 1.93 score on a scale
Phase 3 N=130 A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Change in Ocular Itching Score by Visit — -0.6; -0.9; -1.3; -1.7 score
Phase 4 N=79 Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Change in Ocular Itch Score From Baseline — -1.5; -1.5 units on a scale — p=0.532
Phase 3 N=228 A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.
Allergic Conjunctivitis
Primary: Ocular Itching — 1.609; 1.886; 2.219; 1.750 units on a scale — p=< 0.0001